Future University In Egypt (FUE)

Staff Research

Paper Title :
Author : Doaa Hamed
CoAuthors : Eman Ibrahim El-Desoki Mahmoud,Sherief Abd-Elsalam and Noha O. Mansour
Source : Frontiers Pharmacology
Date of Publication : 07/2021
Abstract : Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these alternative regimens remains unclear. Objective: To compare the efficacy of midodrine/octreotide to that of norepinephrine for the treatment of patients with hepatorenal syndrome. Methods: In the intensive care setting, sixty patients with hepatorenal syndrome were randomized to initially receive either 0.5 mg/h of norepinephrine (maximum 3 mg/h) or 5 mg of oral midodrine three times/day (maximum 12.5 mg three times/day) plus octreotide (100 μg/6 h) as subcutaneous injection (maximum 200 μg/6 h), together with albumin (20–40 g/day). Treatment was allowed for a maximum of 10 days. Survival was analyzed for up to 30 days. The primary efficacy outcome was the proportion of patients who achieved full response, defined as the return of serum creatinine to a value within 0.3 mg/dl of the baseline at the end of treatment. Results: There was a significantly higher rate of full response in the norepinephrine group (15/26, 57.60%) than the midodrine/octreotide group (5/25, 20%) (p = 0.006). Eleven (42.30%) patients in the norepinephrine group and 6 (24%) in the midodrine/octreotide group survived (p = 0.166). Conclusion: Norepinephrine plus albumin is significantly more effective than midodrine and octreotide plus albumin in improving renal function in patients with hepatorenal syndrome.
Download PDF
BACK
  • Research Centers

    With the growing emphasis on collaborative and interdisciplinary science, Research Centers have become indispensable to highly ranked universities. They gain their importance from the outstanding role they play in enhancing the academic activities, in general, and post graduate reputation and scientific ranking in particular. Realizing this fact, Future University in Egypt (FUE) have decided and allocated sufficient funds and infrastructure to establish FUE Research Center (FUERC) having the following vision, mission, and goals

    read more
  • Continuing Education

    Future University in Egypt’s Department of Continuing Education (DCE) is dedicated to bridging the gap between the capabilities

    read more
  • FUE Pharmaceutical Factory

    The Future Factory for Industrial Training’s (FFIT) aim is to be recognized for its unique training facility as well as its advanced techniques. As a result, we established a training pharmaceutical plant, that provides an actual simulation of an industrial atmosphere with the processes and procedures that take place in the manufacturing world.

    read more
  • FUE Dental Hospital

    FUE has maintained a highly reputable dental faculty over the years, therefore the development of the Dental Hospital is a step towards the FUE goal of providing the best dental academic programs

    read more
Community service unit at Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, launches Q&A about Covid-19.

Community service unit at Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, launches Q&A about Covid-19.

COVID-19 Awareness
FUEscientificJournals

VISIT FUE

Take a step to<br>Future<br>For a better future

Address

End of 90th St., Fifth Settlement,
New Cairo, Egypt

Hotline

Inside Egypt: 16383 (16FUE)

Outside Egypt: +20216383, +2026186100

Copyright © 2023 [Future University in Egypt]. All rights reserved.